16:58 , Mar 22, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes Patient sample and yeast studies suggest promoting ZMPSTE24 expression could help treat Type II diabetes. Whole-exome sequencing of patients and healthy volunteers identified associations between loss-of-function mutations in ZMPSTE24 and the disease. In a...
00:15 , Mar 10, 2018 |  BC Extra  |  Preclinical News

Increasing ZMPSTE24 could help treat, prevent Type II diabetes

A study published in Cell showed that the yeast homolog of zinc metallopeptidase STE24 (ZMPSTE24) reduced islet amyloid polypeptide (IAPP) oligomer-induced proteotoxicity by declogging aggregates found in pancreatic beta cells, suggesting that increasing ZMPSTE24 could...
01:59 , Dec 1, 2016 |  BC Innovations  |  Targets & Mechanisms

Not a peripheral story

By sourcing T cells directly from the pancreatic islets of Type I diabetes patients, rather than the standard method of taking blood samples, an academic team has provided an unprecedented view into the molecules that...
07:00 , Aug 28, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Islet amyloid polypeptide (IAPP) In vitro and mouse studies suggest enhancing b cell autophagy could...
07:00 , Sep 30, 2013 |  BC Week In Review  |  Company News

KalVista ophthalmic news

KalVista joined the Drug Discovery and Development of Novel Eye Therapeutics (3D-NET) consortium. The four-year project is developing new drugs to treat ocular disease associated with inflammation, neovascularization, edema and degeneration. The project is funded...
07:00 , Sep 20, 2010 |  BioCentury  |  Product Development

Clearing The Cobwebs

Roche is placing a bet that reMYND N.V.'s approach to clearing misfolded proteins from the CNS could yield disease-modifying treatments for Alzheimer's disease and Parkinson's disease. Proving it will require the partners to develop a...
07:00 , Aug 28, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Endocrine disease ...
07:00 , Jul 18, 2005 |  BioCentury  |  Emerging Company Profile

Innodia: Surrounding diabetes

In a slight twist on the typical NRDO business model, Innodia Inc. has no internal research capabilities of its own, relying on a network of academic and corporate partnerships to in-license Type II diabetes candidates...
07:00 , May 21, 2001 |  BC Week In Review  |  Company News

Crucell, University Medical Center Utrecht deal

CRXL will use its MAbstract phage display technology to identify targets and develop antibodies, and its PER.C6 cell line expression platform to develop vaccines for Type II diabetes. Resulting compounds will be tested in the...